Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An
Acta Pharmaceutica Sinica B
;
(6): 1607-1616, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-888823
ABSTRACT
Remdesivir (RDV) is the only US Food and Drug Administration (FDA)-approved drug for treating COVID-19. However, RDV can only be given by intravenous route, and there is a pressing medical need for oral antivirals. Significant evidence suggests that the role of the parent nucleoside GS-441524 in the clinical outcomes of RDV could be largely underestimated. We performed an
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
Acta Pharmaceutica Sinica B
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS